Document is current

Any future updates will be listed below

How to determine post-FCR therapy for cytogenetic risk-tailored elderly patients with chronic lymphocytic leukemia, maintenance rituximab or observation

Crossref DOI link: https://doi.org/10.1007/s12032-014-0104-7

Published Online: 2014-07-02

Published Print: 2014-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark